Nivolumab has antitumour activity in patients with metastatic renal cell carcinoma (mRCC), according to a phase II trial. Motzer and co-workers randomly assigned 168 patients with clear cell mRCC to one of three doses of nivolomab (0.3 mg/kg, 2 mg/kg and 10 mg/kg) given intravenously once every 3 weeks. Median progression-free survival ranged from 2.7 months to 4.2 months and no dose–response relationship was found. The investigators reported the safety profile to be manageable, with most treatment-related adverse events being of low severity.
References
Motzer, R. J. et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J. Clin. Oncol. 10.1200/JCO.2014.59.0703
Rights and permissions
About this article
Cite this article
Nivolumab in metastatic renal cell carcinoma. Nat Rev Urol 12, 63 (2015). https://doi.org/10.1038/nrurol.2014.347
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2014.347